Russia’s Axelpharm demands compulsory license on Pfizer’s cancer drug Bosulif
The Russian drugmaker Axelpharm is demanding a compulsory license for an antitumor drug based on Bosulif (bosutinib), marketed by US pharma giant Pfizer (NYSE: PFE), reports The Pharma Letter’s local correspondent.
The drug’s purchases at state auctions level in Russia in 2023 were 681 million roubles ($75 million) and in high demand among local customers.
According to Russian Kommersant business paper, recently the Moscow Arbitration Court accepted Axelpharm’s claim against Wyeth Holdings (which Pfizer acquired in 2009) and Rospatent for a compulsory license of the drug. Among the Axelpharm’s registered generics, there is a drug developed by Wyeth Holdings - bosutinib, which is used for chronic myeloid leukemia.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze